News » Dr. Thaleia Papadopoulou
Browse All Categories
Dr. Thaleia Papadopoulou

Dr. Thaleia Papadopoulou

Ph.D. educated Molecular Biologist with extensive experience in Life Sciences and expertise in the fields of Epigenetics, Stem Cells, and Transcriptional Regulation.

More from Dr. Thaleia Papadopoulou

Dr. Thaleia Papadopoulou
By Dr. Thaleia Papadopoulou
on June 30, 2022

Authors: Chong Yang Gue and Dr. Thaleia Papadopoulou

If you missed How Pharmaceutical Companies Can Implement Agile Methodology Part 1 of 2  about how to successfully implement Agile in pharma, we suggest you start there to learn about general Agile development methodology and, specifically, how it can be incorporated in an Agile pharmaceutical development environment. In part 2 we look at the tests and approval approaches adopted in Agile applications within GxP scenarios. 

Dr. Thaleia Papadopoulou
By Dr. Thaleia Papadopoulou
on March 22, 2022

Authors: Chong Yang Gue and Dr. Thaleia Papadopoulou

In a constantly changing world that is dominated by uncertainty, many industries have already adopted Agile software practices, aiming at enhancing flexibility within their business processes and enabling innovation. Although the medical device sector has already embraced Agile within their systems and business organization, the pharmaceutical industry is still behind, mostly due to compliance concerns and misconceptions regarding regulatory expectations in a GxP environment.

Dr. Thaleia Papadopoulou
By Dr. Thaleia Papadopoulou
on October 13, 2021

In this 2nd part of the article series, we discuss the main outcomes in respect to eSource and EHRs in context with current regulations and expert views.

Dr. Thaleia Papadopoulou
By Dr. Thaleia Papadopoulou
on September 27, 2021

Global collaboration between regulatory agencies and health authorities became of paramount importance during the COVID-19 pandemic. Not only allowed it regulators to continue their inspections and surveillance function, but the cooperation also enabled the rapid development and approval of treatments and vaccines against the coronavirus SARS-CoV-2.